Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (NASDAQ: QDEL) is a global leader in diagnostic healthcare solutions, specializing in rapid testing technologies that inform critical clinical decisions. This news hub provides investors and healthcare professionals with timely updates on the company's innovations, regulatory milestones, and market developments.
Access official press releases and curated analysis covering financial results, product launches, strategic partnerships, and advancements in immunoassay or molecular diagnostic technologies. Our repository simplifies tracking of QDEL's contributions to transfusion safety, infectious disease detection, and clinical chemistry solutions across 100+ countries.
Bookmark this page for direct access to essential updates about FDA clearances, international expansion efforts, and research breakthroughs. All content is sourced from verified channels to ensure accuracy in reporting on this NASDAQ-listed innovator's role in shaping diagnostic medicine.
QuidelOrtho (Nasdaq: QDEL) launched the QUICKVUE Influenza + SARS Test, a CLIA‑waived, 510(k)‑cleared rapid immunoassay for professional use that detects and differentiates influenza A, influenza B and SARS‑CoV‑2 antigens from a single nasal swab.
The visually read combo test delivers results in as fast as 10 minutes, is designed for physician office labs, urgent care, emergency departments, pharmacies and decentralized hospital labs, and complements QuidelOrtho's instrumented SOFIA 2 Flu + SARS product as a cost‑effective point‑of‑care option. The test is available in the United States through existing distribution channels and is not intended for in‑home use.
QuidelOrtho (Nasdaq: QDEL) reported Q3 2025 total revenue of $700 million and an adjusted diluted EPS of $0.80. GAAP results included a $701 million non-cash goodwill impairmentGAAP net loss of $733 million and GAAP diluted loss per share of $10.78. Adjusted EBITDA was $177 million with a 25% margin. The company completed a debt refinancing to improve financial flexibility and narrowed full-year 2025 guidance to $2.68–$2.74 billion revenue, $585–$605 million adjusted EBITDA, and $2.00–$2.15 adjusted diluted EPS. Q3 results reflected a 63% decline in COVID-19 revenue and continued wind-down of the U.S. Donor Screening portfolio.
QuidelOrtho (Nasdaq: QDEL) announced FDA 510(k) clearance for the VITROS hs Troponin I Assay on November 3, 2025.
The assay measures cardiac troponin I in human plasma (heparin) to aid diagnosis of myocardial infarction and integrates with existing VITROS Systems and workflows. The company said U.S. commercial rollout for laboratories running VITROS Systems will begin later this year. QuidelOrtho highlighted studies showing hs troponin pathways can reduce 30-day mortality by 12% and 1-year mortality by 10% in suspected acute coronary syndrome patients.
QuidelOrtho (Nasdaq: QDEL) released Episode 52 of its Science Bytes podcast on October 23, 2025, titled "The Power of Informatics in Clinical Decision-Making." The episode features George Wierschem, Senior Global Product Manager – Informatics, who draws on over 30 years of laboratory experience to explain how informatics platforms connect instruments, data systems and clinical decisions.
Key takeaways include:
- Instant insight: turning data into decisions
- Smarter workflows: automation reduces errors and speeds results
- Point-of-care confidence: quality across decentralized testing
- Built-in security: cyber-safe systems without slowing operations
- Trustworthy data: full tracking and accountability
The episode highlights informatics' role in improving lab efficiency, data integrity and patient care. The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) will report its Third Quarter 2025 financial results for the period ended September 28, 2025 after market close on Wednesday, November 5, 2025.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results, with presentation materials posted to the Events & Presentations section of the investor relations website at the time of the call.
Live access: webcast via https://ir.quidelortho.com; phone dial-in: 833-470-1428 (US) or +1 929-526-1599 (international) using Conference ID 415850. A replay will be available on the investor relations site shortly after the event.
QuidelOrtho (Nasdaq: QDEL) will highlight its transfusion medicine portfolio at the AABB 2025 Annual Meeting on Oct 16–17, 2025, following the FDA approval of the MTS™ DAT Card.
The MTS DAT Card completes the company's gel-based direct antiglobulin testing solution and, when paired with the ORTHO VISION™ Platform, offers column agglutination technology with software features like reflex testing and as-needed quality control to speed and standardize transfusion decisions.
Planned activities include education sessions on Rh(D) antigen and DARA interference, poster data on IgG/C3 detection and instrumentation reliability, and product demos of ORTHO VISION Max Swift, ORTHO VISION Swift (noting 98% uptime), and ORTHO CONNECT lab management software.
QuidelOrtho (NASDAQ: QDEL) has released Episode 51 of its Science Bytes podcast featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros. The episode, titled "Through the Shades of Illness, Testing Brings Clarity," focuses on the importance of diagnostic testing in distinguishing between respiratory illnesses with similar symptoms.
Dr. O'Neil, drawing from over 20 years of emergency and urgent care experience, emphasizes how conditions like strep, flu, RSV, and COVID-19 can present similar symptoms, making accurate testing crucial for proper treatment and community health protection. The podcast highlights urgent care centers' vital role in providing immediate access to testing and treatment during respiratory season.
QuidelOrtho (NASDAQ: QDEL) has launched the QUICKVUE Influenza + SARS Test, a professional-use diagnostic tool that simultaneously detects and differentiates between influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample. The CLIA-waived, 510(k)-cleared test delivers results in as fast as 10 minutes.
The test is designed for use in physician office laboratories, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs. Key features include triple detection capability, fast results, professional use designation, efficient workflow with easy-to-collect nasal swabs, and cost-effective visual combo testing. The product is available in the United States through QuidelOrtho's existing distribution channels but is not intended for in-home use.
QuidelOrtho (NASDAQ: QDEL), a global provider of in vitro diagnostic technologies, announced its participation in the upcoming Baird 2025 Global Healthcare Conference. The company's management team will engage in a fireside chat on September 10, 2025, at 3:10 p.m. ET.
Investors and interested parties can access the live webcast and replay through QuidelOrtho's investor relations website. The company specializes in diagnostic solutions for point-of-care settings, clinical laboratories, and transfusion medicine.
QuidelOrtho (NASDAQ: QDEL) has successfully completed a comprehensive debt refinancing initiative to strengthen its capital structure. The refinancing package includes a $1.15 billion 5-year senior secured Term Loan A, a $100 million delayed draw Term Loan A, a $1.45 billion 7-year senior secured Term Loan B, and a $700 million revolving credit facility.
The restructuring extends debt maturities and reduces required amortization payments, providing enhanced financial flexibility. CFO Joseph Busky emphasized that reducing total debt and net debt leverage remains the company's primary capital allocation priority.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
